Market LIVE
Published markets; coverage varies by country
Product profile · United States

SYNJARDY

 ·  Patent Litigation & Settlement History ↓

IngredientEMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Application typeNDA
Application206111
Product001
Dosage formTABLET
RouteORAL
Strength5MG;500MG
Approval date2015-08-26
Marketing statusPrescription
Status event—
ApplicantBOEHRINGER INGELHEIM
Product source

Current GenericRadar decision

Year—
SelectionEXISTING_GENERIC
ReviewCOMPLETED
Anchor type—
Anchor date—
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2022-07-07
Status event—

Final ANDA candidate 212198/001 on 2022-07-07. Source-level RLD/TE screen; earliest Final and exact Product source reference require independent review.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
77139382027-04-15DS/DP ————
———
77139382027-10-15— ————
—2027-10-15—
75794492028-08-01DS ————
———
75794492029-02-01— ————
—2029-02-01—
121151792030-02-11U U-4023———
———
121151792030-08-11— ————
—2030-08-11—
106104892030-09-30DP ————
———
106104892031-03-30— ————
—2031-03-30—
125278102033-04-22U U-4403———
———
125278102033-10-22— ————
—2033-10-22—
102586372034-04-03U U-2290———
———
110903232034-04-03U U-3193———
———
116665902034-04-03U U-4154———
———
118132752034-04-03U U-3759———
———
118331662034-04-03U U-3776———
———
118331662034-04-03U U-3777———
———
122631532034-04-03U U-4154———
———
124271622034-04-03U U-4287———
———
124339062034-04-03U U-4293———
———
124339062034-04-03U U-4295———
———
124339062034-04-03U U-4304———
———
124339062034-04-03U U-4294———
———
124339062034-04-03U U-4296———
———
99499972034-05-17U U-3533———
———
99499972034-05-17U U-3532———
———
102586372034-10-03— ————
—2034-10-03—
110903232034-10-03— ————
—2034-10-03—
118132752034-10-03— ————
—2034-10-03—
118331662034-10-03— ————
—2034-10-03—
124339062034-10-03— ————
—2034-10-03—
99499972034-11-17— ————
—2034-11-17—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NPP—2026-06-20————Source
PED—2026-12-20————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
212373 / 001APPLICATION_TENTATIVE_OBSERVATION · TENTATIVE_PRODUCT_SCOPE_UNVERIFIED——MACLEODS PHARMS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212198 / 001FINAL_APPROVAL · FINAL_APPROVED2022-07-07—ZYDUS PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 1 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
212198 / 001ZYDUS PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2022-07-07 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.